Abstract AP19: COLLAGEN ALTERATIONS IN HUMAN OVARIAN CANCER PROBED BY SECOND HARMONIC GENERATION (SHG) IMAGING MICROSCOPY
Authors: Kirby R. Campbell, Rajeev Chaudhary, Julia Handel, Bruce Wen, Vikas Singh, Manish Patankar, Paul J. Campagnola
Journal: Clinical Cancer Research (2019)

Abstract PURPOSE: Significant remodeling of the extracellular matrix (ECM) occurs in human ovarian cancer and has been observed in both high grade and low grade tumors as well as ovaries from high risk patients with BRCA mutations. Uniquely quantifying alterations in the tumor microenvironment (TME) could be used as a new diagnostic tool, e.g. to complement histology; provide insight into disease etiology; and assess treatment efficacy through minimally invasive in vivo imaging. Current clinical modalities (CT, MRI, PET) lack the resolution for this purpose. Our efforts have focused on examining collagen alterations across a spectrum of human ovarian tumors, where the changes can serve as quantitative biomarkers. Alterations can be reflected in increased collagen concentration, changes in alignment of collagen molecules within fibrils and/or fibers and/or up-regulation of different collagen isoforms, e.g. Col III. METHODS AND RESULTS: We used the collagen specific/sensitive Second Harmonic Generation (SHG) imaging microscopy to probe collagen architecture over size scales that range from the macromolecular structural properties to fibril/fiber morphology. First, we used SHG polarization analyses to probe collagen macromolecular/supramolecular properties to discriminate ex vivo human tissues (normal stroma, benign tumors, and high grade serous tumors) by determination of: i) collagen alpha helical pitch angle, ii) alignment of collagen molecules within fibrils, and iii) collagen helical chirality via SHG circular dichroism (SHG-CD). The largest differences were between normal stroma and benign tumors, consistent with gene expression data showing Col III is up-regulated in the latter. The different tissues also displayed differing collagen alignment within fibrils and SHG-CD responses, consistent with either Col III incorporation or randomization of Col I alignment within benign and high-grade tumors fibrils. These results collectively indicate the fibril assemblies are distinct in all tissues and likely result from synthesis of new collagen rather than remodeling of existing collagen. Importantly, these techniques do not require exogenous labels, and additionally, provide sub-resolution structural information previously obtained through ultrastructural analysis that cannot be performed on intact tissues. We next implemented a novel form of 3D texture analysis and machine learning to delineate the fibrillar morphology observed in SHG images of normal stroma, high risk stroma, benign tumors, and a spectrum of malignant tumors (high grade serous, low grade serous, and endometrioid). We extracted textural features in the 3D image sets to build statistical models of each class and we achieved clinically significant 83-91% classification accuracies for the six classes. Importantly, the 3D analysis significantly outperformed our prior 2D methods. This classification based on collagen morphology will complement conventional classification based on genetic profiles and can serve as an additional biomarker. CONCLUSIONS: Taken together, the combination of the macro/supramolecular probes and the fiber morphology classification will greatly increase our understanding of the TME evolution in human ovarian cancer. These methods and their findings have clinical translational significance in terms of understanding disease etiology, and also by enhancing prognostic and diagnostic capabilities. Citation Format: Kirby R. Campbell, Rajeev Chaudhary, Julia Handel, Bruce Wen, Vikas Singh, Manish Patankar and Paul J. Campagnola. COLLAGEN ALTERATIONS IN HUMAN OVARIAN CANCER PROBED BY SECOND HARMONIC GENERATION (SHG) IMAGING MICROSCOPY [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr AP19.